Vera Therapeutics shares are trading higher after the company reported 96-week eGFR stabilization on Saturday for its Phase 2b study of IgAN patients with Atacicept.
Portfolio Pulse from Benzinga Newsdesk
Vera Therapeutics shares rose following positive results from a 96-week eGFR stabilization in their Phase 2b study of IgAN patients using Atacicept.

October 28, 2024 | 12:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vera Therapeutics shares increased due to positive results from their Phase 2b study showing 96-week eGFR stabilization in IgAN patients treated with Atacicept.
The positive results from the Phase 2b study are likely to boost investor confidence in Vera Therapeutics' product pipeline, leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100